“Don’t panic, this is the victory of the virus,” said Bernard Kouchner, co-founder of Medecins Sans Frontieres (Doctors Without Borders).
“Don’t panic, this is the victory of the virus,” said Bernard Kouchner, co-founder of Medecins Sans Frontieres (Doctors Without Borders).
The former French Foreign Minister jokingly urged the audience at American Museum of Natural History in New York City on October 28 not to rush for the exits even though he was fresh off a trip to Ebola afflicted Guinea.
Kouchner spoke about the need to keep separate humanitarian aid efforts and politics as he received the 2014 Pro Bono Humanum Award at the eighth annual Prix Galien USA Awards ceremony.
“At the beginning of the epidemic, in January, only one organization was there, taking care of these patients… In Liberia, Sierra Leone and Guinea, it was the very brave, dedicated and efficient people of doctor’s without borders,” he said. “They are patients and we have to help them,” added Kouchner.
Earlier at the Prix Galien Forum, Kouchner spoke on the group’s efforts in Africa.
The story of Ebola, “is a story of globalization, of rich versus poor”, he said. Response to Ebola by the rest of the world has been late and slow, but it is now good, Kouchner added. What is desperately needed, more so than monetary contributions, is leadership in the stricken nations.
The awards ceremony is viewable here with Kouchner’s speech coming at 36:35.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.